Taiji Group: Clinical trial of subsidiary Shuang Ling Stopping Diarrhea Granules approved.

On April 13th, Tai Chi Group announced that its wholly-owned subsidiary, Tai Chi Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., recently received the Drug Clinical Trial Approval Notice for Shuang Ling Anti-Diarrhea Granules issued by the National Medical Products Administration. This drug is a category 2.2 improved traditional Chinese medicine, developed by the company as a reformulated version of their exclusive product, Shuang Ling Anti-Diarrhea Oral Liquid, intended for the treatment of acute infantile diarrhea with damp-heat syndrome. Up to now, the company has invested approximately 5.7879 million yuan in research and development expenses for this project. The company will soon initiate clinical trials and related pharmaceutical research work, and will apply for production and marketing after the completion of the trials and research. Given the high risk and long cycle characteristics of pharmaceutical research and development, there is uncertainty in the subsequent progress.